PBAC's latest decision on Erlotinib: Recommended with restriction (2013). Considered for Initial and continuing first-line treatment, as monotherapy, of locally advanced (stage IIIB) or metastatic (stage IV) non-squamous or not otherwise specified (NOS) non-small cell lung cancer in patients with evidence of activating mutation(s) of the epidermal growth factor receptor (EGFR) gene in tumour material, who do not have progressive disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
5
first 2006
Submissions
5
2006 → 2013
Eligible population
Adults with locally advanced (stage IIIB) or metastatic (stage IV) non-squamous or NOS non-small cell lung cancer with evidence of activating mutation(s) of the EGFR gene, WHO/ECOG performance status 0 to 2, with no evidence of progressive disease.
platinum-based doublet chemotherapy (carboplatin and gemcitabine); gefitinib
ICER note
ICER not stated in this PSD; economic model details not presented in the public summary.
ICER (historical)
$15k/QALY–$45k/QALY across 4 submissions (2006–2012) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2006: Not recommended — ICER $75k/QALY
Nov 2006: Not recommended · Authority Required — ICER $75k/QALY
Nov 2007: Deferred — ICER $75k/QALY
Jul 2012: Recommended with restriction — ICER $45k/QALY
Jul 2013: Recommended with restriction · Authority Required